Truscreen Group

Truscreen Group EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Truscreen Group (TRU.NZ) as of Oct 30, 2026 is -6.83. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -6.38 — a change of 7.17% (lower).

EV/FCF

-6.83

YoY

7.17%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Truscreen Group is 2025 -6.83 . EV/FCF (Enterprise Value to Free Cash Flow) of Truscreen Group was 2024 -6.38 . It decreases by 7.17% lower compared to the previous year.

The Truscreen Group EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-4.41 NZD
Jan 1, 2018
-3.88 NZD
Jan 1, 2019
-4.72 NZD
Jan 1, 2020
-9.23 NZD
Jan 1, 2021
-4.56 NZD
Jan 1, 2022
-5.09 NZD
Jan 1, 2024
-6.38 NZD
Jan 1, 2025
-6.83 NZD
The Truscreen Group EV/FCF history
YEAREV/FCFYoY
-6.83+7.17%
-6.38+25.32%
-5.09+11.48%
-4.56-50.52%
-9.23+95.39%
-4.72+21.70%
-3.88-12.12%
-4.41-9.62%
-4.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Truscreen Group Stock analysis

What does Truscreen Group do? TruScreen Group Ltd develops and sells cancer detection devices and systems, focusing on cervical cancer screening. The company's AI-enabled device uses opto-electrical technology to detect precancerous and cancerous cervical changes in real-time through optical and electrical measurements of cervical tissue. The TruScreen device includes a Disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC), working together to resolve issues with cytology such as failed samples, poor patient follow-up, and patient discomfort. The company also addresses challenges with HPV testing by providing an alternative solution that avoids the need for laboratory infrastructure. The primary buyers of TruScreen's products are healthcare providers and clinics specializing in women's health, particularly those seeking efficient, real-time cervical screening solutions. The technology targets segments where traditional cytology and HPV testing face limitations, such as in resource-constrained settings or where patient adherence to follow-up is low. By offering a device that eliminates the need for supporting laboratory infrastructure, TruScreen appeals to providers looking to streamline cervical cancer screening processes. TruScreen's products are designed to replace or complement existing cervical screening methods, directly addressing the shortcomings of cytology and HPV testing. The company's focus on real-time detection and ease of use positions it as a solution for healthcare systems aiming to improve early cancer detection rates while reducing patient discomfort and logistical challenges associated with current screening practices. Truscreen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Truscreen Group stock

EV/FCF (Enterprise Value to Free Cash Flow) of Truscreen Group is -6.83 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Truscreen Group changed from -6.38 to -6.83, representing a 7.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Truscreen Group since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Truscreen Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Truscreen Group

All Key Metrics — Truscreen Group